We are live on
!
Find out more
ACM
Atika Capital Management Portfolio holdings
AUM
$796M
1-Year Est. Return
167.57%
This Fund
S&P 500
This Quarter
Est. Return
+20.03%
1 Year Est. Return
+167.57%
3 Year Est. Return
+553.47%
5 Year Est. Return
+1,283.26%
10 Year Est. Return
+44,203.78%
AUM
$999M
AUM Growth
+$322M
(+48%)
Cap. Flow
+$45.4M
Cap. Flow
% of AUM
4.54%
Top 10 Holdings %
Top 10 Hldgs %
35.96%
Holding
110
New
33
Increased
25
Reduced
21
Closed
27
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
EXAS
Exact Sciences
EXAS
|
+$19M |
| 2 |
Tenet Healthcare
THC
|
+$18M |
| 3 |
Fortinet
FTNT
|
+$12.8M |
| 4 |
Datadog
DDOG
|
+$12.3M |
| 5 |
RxSight
RXST
|
+$11.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TSMC
TSM
|
+$9.4M |
| 2 |
Advanced Micro Devices
AMD
|
+$9.11M |
| 3 |
Rapid7
RPD
|
+$8.72M |
| 4 |
Tesla
TSLA
|
+$8.51M |
| 5 |
XYZ
Block Inc
XYZ
|
+$8.24M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.36% |
| 2 | Technology | 25.88% |
| 3 | Communication Services | 6.54% |
| 4 | Industrials | 5.56% |
| 5 | Materials | 4.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
PUT
Viking Therapeutics
VKTX
$3.89B
| $2.43M | 0.24% |
+1,500
| New | +$31.4K |
|
|
77
TSMC
TSM
$2.16T
| $2.42M | 0.24% |
24,000
-101,000
| -81% | -$9.4M |
|
|
RETA
78
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $2.24M | 0.22% |
+22,000
| New | +$2.08M |
|
79
CALL
Sotera Health
SHC
$5.35B
| $1.74M | 0.17% |
+925
| New | +$14.7K |
|
|
VISN
80
CALL
Vistance Networks Inc
VISN
$2.37B
| $1.69M | 0.17% |
3,000
| – | – |
|
81
FIVE9
FIVN
$2.57B
| $1.48M | 0.15% |
18,000
-21,000
| -54% | -$1.41M |
|
|
AVID
82
DELISTED
Avid Technology Inc
AVID
| $720K | 0.07% |
28,231
-190,769
| -87% | -$4.94M |
|
83
Orchestra BioMed
OBIO
$253M
| $453K | 0.05% |
+64,651
| New | +$981K |
|
|
84
Advanced Micro Devices
AMD
$783B
| – | – |
-93,000
| Closed | -$9.11M |
|
85
CALL
BridgeBio Pharma
BBIO
$16.2B
| – | – |
-1,020
| Closed | -$1.69M |
|
|
86
BridgeBio Pharma
BBIO
$16.2B
| – | – |
-90,000
| Closed | -$1.49M |
|
87
Blackbaud
BLKB
$2.11B
| – | – |
-60,000
| Closed | -$4.16M |
|
88
PUT
CareDx
CDNA
$2.37B
| – | – |
-73
| Closed | -$66.7K |
|
89
Clearfield
CLFD
$372M
| – | – |
-45,600
| Closed | -$2.12M |
|
90
Corteva
CTVA
$51.3B
| – | – |
-121,000
| Closed | -$7.3M |
|
91
Cytokinetics
CYTK
$10.4B
| – | – |
-75,063
| Closed | -$2.64M |
|
|
GBIO
92
DELISTED
Generation Bio
GBIO
| – | – |
-35,500
| Closed | -$1.53M |
|
|
GTLS
93
DELISTED
Chart Industries
GTLS
| – | – |
-20,500
| Closed | -$2.57M |
|
94
Illumina
ILMN
$28.9B
| – | – |
-20,560
| Closed | -$4.65M |
|
95
Jazz Pharmaceuticals
JAZZ
$16.6B
| – | – |
-26,500
| Closed | -$3.88M |
|
96
CALL
Manchester United
MANU
$3.79B
| – | – |
-1,720
| Closed | -$3.81M |
|
|
MPT
97
PUT
Medical Properties Trust
MPT
$2.77B
| – | – |
-5,000
| Closed | -$4.11M |
|
98
Procore
PCOR
$8.64B
| – | – |
-47,500
| Closed | -$2.97M |
|
99
Pliant Therapeutics
PLRX
$64.4M
| – | – |
-109,190
| Closed | -$2.9M |
|
100
Regeneron Pharmaceuticals
REGN
$79.9B
| – | – |
-9,690
| Closed | -$7.96M |
|
Similar funds
AGA
ACM
LSA
GWA
HP
SC
IAM
VCM
Atika Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Atika Capital Management held 110 positions worth $999M, up 48% from $677M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Atika Capital Management deployed $45.4M of net new capital in Q2 2023, opening 33 new positions and adding to 25 existing holdings. Its largest new stake was Exact Sciences: 243,000 shares worth $22.8M.
By sector, the portfolio is most concentrated in Healthcare at 30% of assets, up from 30% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was TSMC, an estimated $9.4M trimmed.
- Atika Capital Management's largest Q2 2023 buy was Exact Sciences: 243,000 shares worth $22.8M.
- Atika Capital Management added most to Datadog in Q2 2023, an estimated $12.3M increase.
- Atika Capital Management's biggest Q2 2023 reduction was TSMC, cutting an estimated $9.4M.
- Atika Capital Management fully exited Advanced Micro Devices in Q2 2023, selling an estimated $9.11M.
- Atika Capital Management's ten largest holdings make up 36% of its $999M portfolio in Q2 2023.
- Atika Capital Management opened 33 new positions and closed 27 in Q2 2023.
- Atika Capital Management's portfolio value rose 48% quarter-over-quarter to $999M.
Based on Atika Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.